Friday, 19 Jul 2019

You are here

EULAR 2019 Report – Day 2

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. It was a full and lively second day in Madrid with sessions dedicated to Lupus, RA, Sjogren’s, imaging, rare diseases, psoriatic arthritis and spondyloarthritis. Here are a few of the highlights from day 2 EULAR in Madrid. 

  • Riociquat in SSc-ILD: riociquat is approved in the US for pulmonary arterial hypertension and chronic thromboembolic pulmonary HTN and is now applied to 121 patients with early SSc (<18 mos. Symptoms) and limited scleroderma (mRSS 12-20).  This 52 week ended with a downward trend in skin thickness but did not achieve its primary endpoint (p=0.08).  However when they looked at the 20% of patients who had interstitial lung disease, they found significant reductions in FVC. This was encouraging as the drug was well tolerated.  OP0183
  • The Earlier the Better.  A longitudinal study from a Swedish RA registry examine 6559 RA patients enrolled since 1991 and shown that new, DMARD naïve RA patients, have overtime, demonstrated decreasing levels of joint activity (initial SJC, TJC), CRP, ESR, and increasing patient and evaluator global assessments.  Also decreasing was the time from symptom onset to diagnosis of RA.  So if RA is getting milder, it may well be that we are seeing them sooner, with more expedited diagnoses and hopefully earlier DMARD initiation.  THU0073
  • Machine Learning with Psoriatic Arthritis.  Dr. Ian McInnes presented a novel and futuristic analysis of PsA patients by applying “machine learning” to the secukinumab PsA trials that included >2,700 patients to identify clusters that may lead to more personalized treatment.  Overall they defined 13 clusters of PsA based on patterns of tender joint (TJ) and swollen joint (SJ) involvement. They plan on doing further study of other psoriatic manifestations such as skin and nail involvement to describe a range of phenotypes that explains PsA variability.  OP0114

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

RheumNow Podcast – Don’t Take My Advice (7.19.19)

Dr. Jack Cush reports the news and new journal articles from the past week on RheumNow.com.

RheumNow Podcast – Boiling Hot MAS (7.12.19)

Dr. Jack Cush reviews this week's news and journal reports featured on RheumNow.com. PsA v. non-PsA pregnancies, Still's disease, lupus, nutritional supplements and dietary interventions, use of cannabis, tanezumab in OA, CBD oils and more.

Be ‘on point’: Guidelines for rheumatic complications of immunotherapy

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. At EULAR 2019, Madrid, several recommendations including RA, SLE, and Sjogren’s syndrome have been developed. Agreement for principles with respect to the treatment of immune mediated adverse events from cancer immunotherapy are lacking.

RheumNow Podcast – EULAR 2019 Streamin' - (6.14.19)

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. Dr. Jack Cush reports from Madrid on several novel presentations from EULAR 2019, including low-dose steroids in hand OA, ABA vs. ADA in double positive RA patients, psoriasis predictors of PsA, tildrakizumab and more.

EULAR 2019 – Day 3 Report

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. The third day of EULAR 2019 started with novel biologics, the efficacy of secukinumab in axial psoriatic arthritis, neurologic events with TNF inhibitors from the DANBIO database (OP0261), and neuropathy in SLE (OP0252), but above all this was a big poster day. Here are selected highlights from day 3 EULAR in Madrid.